These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fluoroquinolones: a new treatment for tuberculosis? Gillespie SH; Kennedy N Int J Tuberc Lung Dis; 1998 Apr; 2(4):265-71. PubMed ID: 9559396 [TBL] [Abstract][Full Text] [Related]
6. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Sullivan EA; Kreiswirth BN; Palumbo L; Kapur V; Musser JM; Ebrahimzadeh A; Frieden TR Lancet; 1995 May; 345(8958):1148-50. PubMed ID: 7723548 [TBL] [Abstract][Full Text] [Related]
7. The role of fluoroquinolones in tuberculosis today. Berning SE Drugs; 2001; 61(1):9-18. PubMed ID: 11217874 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis. Zhang YJ; Li XJ; Mi KX Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933 [TBL] [Abstract][Full Text] [Related]
9. Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. Tomioka H; Sato K; Shimizu T; Sano C J Infect; 2002 Apr; 44(3):160-5. PubMed ID: 12099742 [TBL] [Abstract][Full Text] [Related]
10. First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant Varghese B; Al-Hajoj S Am J Trop Med Hyg; 2017 May; 96(5):1066-1070. PubMed ID: 28500800 [TBL] [Abstract][Full Text] [Related]
11. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. Huang TS; Kunin CM; Shin-Jung Lee S; Chen YS; Tu HZ; Liu YC J Antimicrob Chemother; 2005 Dec; 56(6):1058-62. PubMed ID: 16204341 [TBL] [Abstract][Full Text] [Related]
12. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis. Eilertson B; Maruri F; Blackman A; Herrera M; Sterling TR Int J Tuberc Lung Dis; 2016 Sep; 20(9):1276-7. PubMed ID: 27510259 [No Abstract] [Full Text] [Related]
13. [The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections]. Wyplosz B; Truffot-Pernot C; Robert J; Jarlier V; Grosset J Rev Mal Respir; 1997 Dec; 14 Suppl 5():S33-48. PubMed ID: 9496590 [TBL] [Abstract][Full Text] [Related]
14. [View of development of fluoroquinolones]. Namba K Kekkaku; 1999 Jan; 74(1):47-52. PubMed ID: 10067055 [TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Jabeen K; Shakoor S; Hasan R Int J Infect Dis; 2015 Mar; 32():118-23. PubMed ID: 25809767 [TBL] [Abstract][Full Text] [Related]
16. How are we creating fluoroquinolone-resistant tuberculosis? Bernardo J; Yew WW Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251 [No Abstract] [Full Text] [Related]
17. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Alangaden GJ; Lerner SA Clin Infect Dis; 1997 Nov; 25(5):1213-21. PubMed ID: 9402384 [TBL] [Abstract][Full Text] [Related]
18. Detection of resistance to fluoroquinolones and injectable drugs among antituberculosis drugs by allele-specific primer extension on a microsphere-based platform. Kim K; Yang JS; Choi HB; Lee SH J Microbiol Methods; 2018 Jan; 144():111-116. PubMed ID: 29129484 [TBL] [Abstract][Full Text] [Related]
19. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Rastogi N; Labrousse V; Goh KS Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093 [TBL] [Abstract][Full Text] [Related]
20. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. van den Boogaard J; Semvua HH; van Ingen J; Mwaigwisya S; van der Laan T; van Soolingen D; Kibiki GS; Boeree MJ; Aarnoutse RE J Antimicrob Chemother; 2011 Aug; 66(8):1810-4. PubMed ID: 21642290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]